Medires Publishers - Article

Archive : Article / Volume 2, Issue 1

Innovative Technique for Muscle Exploration in Patients With COPD

A. MERIDJ*1R. BELAALA1Y. DJEGHRI1

1Service of Pulmonology Military Regional University Hospital of Constantine.

Correspondng Author:

A. MERIDJ*

Citation:

A. MERIDJ, R. BELAALA, Y. DJEGHRI. (2024). Innovative Technique for Muscle Exploration in Patients With COPD. International Journal of Pulmonology and Disorders. 3(1). DOI: 10.58489/3066-0955/007

Copyright:

© 2024 Amine Meridj, this is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • Received Date: 23-09-2024   
  • Accepted Date: 08-11-2024   
  • Published Date: 22-11-2024
Abstract Keywords:

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with numerous comorbidities, including muscle involvement which consists of changes in the structure and function of peripheral and respiratory muscles. Ultrasound can provide a non-invasive assessment of muscle damage. Ultrasound assessment of the quadriceps contractility index (Qci) is feasible, rapid, simple and reliable. Numerous studies have demonstrated that Qci is linked to the severity of COPD, clinical symptoms and respiratory muscle activity. Furthermore, ultrasound makes it possible to observe the dynamics of the diaphragm by measuring its amplitude, its contraction speed and the duration of each contraction phase. Ultrasound examination of muscle damage in COPD could constitute a promising new tool to assess the severity of the disease.

Introduction

GOLD 2023 defines broncho-pneumopathy obstructive chronic disease (COPD) as a“ Heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent obstruction, often progressive, of the airflow” (1).
COPD is a major public health problem with the consequences it brings in terms of morbidity, mortality and disability. Globally, it is estimated that 480 million People had COPD in 2019 (2) and this figure is underestimated (3). According to the BOLD study, 10.1% of people over 40 would have COPD (4).
The increase in tobacco consumption in developing countries as well as the Population ageing in the countries industrial companies will lead to an increase in the prevalence of of COPD in the next 30 years. In 2030, 4.5 million deaths from COPD are expected annually (5).
According to the Global Burden of Diseases, established by the World Health Organization, COPD is the third most deadly disease in the world. She was responsible for 3.23 million deaths in 2019 (5.7% of deaths) (3).
The cost of COPD is estimated in terms of health care and productivity loss a 48.4 billion euros per year for the EU countries
In France, direct cost is estimated at annual cost of the disease to 3.5 billion euro (6).
In Algeria, according to the results of the Breathe study, prevalence of COPD is estimated at 4% in the general population and 25% of smokers (7). Smoking increases this prevalence which 31.5% among smokers, 14.6% among Ex-smokers and 2.5% for non-smokers (8).
COPD is associated with many comorbidities, including lung cancer, cardiovascular disease, osteoporosis, the cachexia and muscle involvement (9).
Muscular atrophy of skeletal muscles is an important general event of COPD.
This dysfunction has multiple causes, including physical inactivity (10) and systemic inflammation (11). Corticosteroid therapy systemic, hypoxemia, hypercapnia, hypersensitivity malnutrition, electrolyte disorders, Heart failure and hypogonadism are also involved (12).
Given the severity of the disease and population, it is estimated that 4 to 35% patients with COPD have a loss of muscle mass (13, 14).
A recent study found that 32% of patients with COPD had a strength of quadriceps below lower limits of Normal and approximately 25% of patients in the GOLD I and II and 38% of patients at stage GOLD IV were affected by muscle weakness (15).
This muscle weakness has several serious consequences, including intolerance to The decline in quality of the financial year (16, 17) life, and increased mortality (18). In patients with a significant decrease of the air flow, the section decrease transverse to the middle of the thigh is associated with a 13 times higher relative mortality risk the one observed in patients whose mass muscular is good (19).
The ultrasound evaluation of the quadriceps contractility (Qci) is feasible, fast, simple and reliable. The ICQ is related to severity of COPD, clinical symptoms and activity of the respiratory muscles. His measurement could a promising new tool for Assess the severity of the disease (20).
The diaphragm is the main muscle of inspiration during resting breathing (21).
It is a striated skeletal respiratory muscle, having a rhythmic activity, permanent, Involuntary, but adjustable by cortical activity. It is a resilient muscle, characterized by high oxidation capacity, a high proportion (60%) of fatigue resistant fibers and a lot of capillaries (22).
Dysfunction of the diaphragmatic muscles plays a significant role in the pathogenesis of respiratory distress in patients with COPD (23).
Traditionally, the weakness of the diaphragm to its shortening caused by hyperinflation, which places the diaphragm in a mechanical disadvantage (24).
However, several more recent studies show that Participation in other phenomena, such as Intrinsic alterations of the diaphragm (25, 26).
In patients with COPD, it has been found that a transition to a higher proportion of Type I fibers compared to subjects healthy (27). Type I fibers produce a force is lower than that of Type II fibers, which improves fatigue resistance (25).
Exogenous oxidative stress caused by exposure Cigarette smoke, biomass and air pollution, oxidative stress endogenous resulting from cell activation inflammatory in the lung and reduction antioxidants leads to an increase in oxidative stress in the lungs. This is a significant factor in pathophysiology of COPD and its evolution, as well as in increased risk of exacerbations acute. Increased oxidative stress in the lungs of patients with COPD leads to a chronic inflammation, a decrease in anti-inflammatory effects of corticosteroids, a rapid aging of the lungs, fibrosis peripheral respiratory tract and a hyperproduction of mucus (28).
Oxidative stress plays an important role in the pathophysiology of COPD (29, 30). Some studies have shown the association between stress oxidative and the severity of COPD leading to Medical comorbidities and dysfunction muscular(31).
Several tools to evaluate directly or indirectly the diaphragm : Measurement of inspiratory pressure and transdiaphragmatic pressure by stimulation magnetic or electrical phreonic nerve, EMG or imaging. The evaluation does not diaphragm selective or invasive nature and very complex of these tools limit their use (32).
In pneumology, ultrasound is still little used in diaphragm exploration while it offers many advantages: is a non-invasive, quick and easy to Can be used especially at the bedside patients with exacerbations COPD, especially with devices portable and ultra-portable (33, 34). This provides possibility of structural analysis and functional of two hemi-diaphragms distinct (35, 36).
Two components of diaphragm function are commonly assessed by ultrasound (32):
−    Subcostal diaphragm excursion anterior and lateral thoracic (EXdi).
−    The thickening fraction of the diaphragm measured at the diaphragm apposition area on the thoracic cage (TFdi).
Thus, thanks to ultrasound, it is possible to observe directly the dynamics of the diaphragm in measuring its amplitude, its contraction rate, the duration of each contraction phase. Being non-irradiant, this examination can be repeated as many times as you want to follow the time-lapse diaphragmatic kinetic (37).
Finally, its cost is lower than that of the others methods of diaphragm exploration.

References

  1. Agustı, A., Celli, B. R., Criner, G. J., Halpin, D., Anzueto, A., Barnes, P., ... & Vogelmeier20, C. F. (2023). PULMONARY PERSPECTIVE. Am J Respir Crit Care Med, 207(7), 819-837.
  2. Murray, C. J., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., ... & Borzouei, S. (2020). Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The lancet, 396(10258), 1223-1249.
  3. Ho, T., Cusack, R. P., Chaudhary, N., Satia, I., & Kurmi, O. P. (2019). Under-and over-diagnosis of COPD: a global perspective. Breathe, 15(1), 24-35.
  4. Buist, A. S., Vollmer, W. M., & McBurnie, M. A. (2008). Worldwide burden of COPD in high-and low-income countries. Part I. The Burden of Obstructive Lung Disease (BOLD) Initiative [State of the Art Series. Chronic obstructive pulmonary disease in high-and low-income countries. Edited by G. Marks and M. Chan-Yeung. Number 6 in the series]. The international journal of tuberculosis and lung disease, 12(7), 703-708.
  5. Halpin, D. M. G., Celli, B. R., Criner, G. J., Frith, P., Varela, L., Salvi, S., ... & Agusti, A. (2019). The GOLD Summit on chronic obstructive pulmonary disease in low-and middle-income countries. The International Journal of Tuberculosis and Lung Disease, 23(11), 1131-1141.
  6. Rehman, A. U., Hassali, M. A. A., Muhammad, S. A., Harun, S. N., Shah, S., & Abbas, S. (2020). The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literature. The European Journal of Health Economics, 21, 181-194.
  7. Uzaslan, E., Mahboub, B., Beji, M., Nejjari, C., Tageldin, M. A., Khan, J. A., ... & BREATHE Study Group. (2012). The burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE study. Respiratory medicine, 106, S45-S59.
  8. Khelafi, R., Aissanou, A., Tarsift, S., & Skander, F. (2011). Épidémiologie de la bronchopneumopathie chronique obstructive dans la wilaya d’Alger. Revue des maladies respiratoires, 28(1), 32-40
  9. Decramer, M., & Janssens, W. (2013). Chronic obstructive pulmonary disease and comorbidities. The Lancet Respiratory Medicine, 1(1), 73-83.
  10. Waschki, B., Kirsten, A., Holz, O., Müller, K. C., Meyer, T., Watz, H., & Magnussen, H. (2011). Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest, 140(2), 331-342.
  11. Spruit, M. A., Gosselink, R., Troosters, T., Kasran, A., Gayan-Ramirez, G., Bogaerts, P., ... & Decramer, M. (2003). Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax, 58(9), 752-756.
  12. Van Vliet, M., Spruit, M. A., Verleden, G., Kasran, A., Van Herck, E., Pitta, F., ... & Decramer, M. (2005). Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 172(9), 1105-1111.
  13. Coronell, C., Orozco‐Levi, M., Mendez, R., Ramírez‐Sarmiento, A., Galdiz, J. B., & Gea, J. (2004). Relevance of assessing quadriceps endurance in patients with COPD. European Respiratory Journal, 24(1), 129-136.
  14. Vestbo, J., Prescott, E., Almdal, T., Dahl, M., Nordestgaard, B. G., Andersen, T., ... & Lange, P. (2006). Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. American journal of respiratory and critical care medicine, 173(1), 79-83.
  15. Seymour, J. M., Spruit, M. A., Hopkinson, N. S., Natanek, S. A., Man, W. C., Jackson, A., ... & Wouters, E. F. M. (2010). The prevalence of quadriceps weakness in COPD and the relationship with disease severity. European Respiratory Journal, 36(1), 81-88.
  16. Bernard, S., LeBlanc, P., Whittom, F., Carrier, G., Jobin, J., Belleau, R., & Maltais, F. (1998). Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 158(2), 629-634.
  17. Nici, L., Donner, C., Wouters, E., Zuwallack, R., Ambrosino, N., Bourbeau, J., ... & Troosters, T. (2006). American thoracic society/European respiratory society statement on pulmonary rehabilitation. American journal of respiratory and critical care medicine, 173(12), 1390-1413.
  18. Pitta, F., Troosters, T., Spruit, M. A., Probst, V. S., Decramer, M., & Gosselink, R. (2005). Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 171(9), 972-977.
  19. Marquis, K., Debigaré, R., Lacasse, Y., LeBlanc, P., Jobin, J., Carrier, G., & Maltais, F. (2002). Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 166(6), 809-813.
  20. Maynard-Paquette, A. C., Poirier, C., Chartrand-Lefebvre, C., & Dubé, B. P. (2020). Ultrasound evaluation of the quadriceps muscle contractile index in patients with stable chronic obstructive pulmonary disease: relationships with clinical symptoms, disease severity and diaphragm contractility. International journal of chronic obstructive pulmonary disease, 79-88.
  21. McCool, F. D., & Tzelepis, G. E. (2012). Dysfunction of the diaphragm. New England Journal of Medicine, 366(10), 932-942.
  22. Charloux A, Enache I. Exploration fonctionnelle des muscles respiratoires. EMC-Pneumologie. 2015;12(3):1-11.
  23. De Blasio, F., Comune, M., Oliva, A., Garello, L., Bucca, C., & Prota, R. (2020). INFLUENCE OF DIAPHRAGM DYSFUNCTION, EXERCISE CAPACITY, AND NUTRITION ON DYSPNEA SEVERITY OF COPD PATIENTS. Chest, 157(6), A417.
  24. Similowski, T., Yan, S., Gauthier, A. P., Macklem, P. T., & Bellemare, F. (1991). Contractile properties of the human diaphragm during chronic hyperinflation. New England Journal of Medicine, 325(13), 917-923.
  25. Levine, S., Nguyen, T., Kaiser, L. R., Rubinstein, N. A., Maislin, G., Gregory, C., ... & Shrager, J. B. (2003). Human diaphragm remodeling associated with chronic obstructive pulmonary disease: clinical implications. American journal of respiratory and critical care medicine, 168(6), 706-713.
  26. Barreiro, E., De La Puente, B., Minguella, J., Corominas, J. M., Serrano, S., Hussain, S. N., & Gea, J. (2005). Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine, 171(10), 1116-1124.
  27. Levine, S., Gregory, C., Nguyen, T., Shrager, J., Kaiser, L., Rubinstein, N., & Dudley, G. (2002). Bioenergetic adaptation of individual human diaphragmatic myofibers to severe COPD. Journal of applied physiology, 92(3), 1205-1213.
  28. Barnes, P. J. (2022). Oxidative stress in chronic obstructive pulmonary disease. Antioxidants, 11(5), 965.
  29. Scicchitano, B. M., Pelosi, L., Sica, G., & Musarò, A. (2018). The physiopathologic role of oxidative stress in skeletal muscle. Mechanisms of Ageing and Development, 170, 37-44.
  30. da Silva Lage, V. K., de Paula, F. A., Dos Santos, J. M., Costa, H. S., da Silva, G. P., Lima, L. P., ... & Mendonça, V. A. (2022). Are oxidative stress biomarkers and respiratory muscles strength associated with COPD-related sarcopenia in older adults?. Experimental Gerontology, 157, 111630.
  31. Sepúlveda‐Loyola, W., Osadnik, C., Phu, S., Morita, A. A., Duque, G., & Probst, V. S. (2020). Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta‐analysis. Journal of cachexia, sarcopenia and muscle, 11(5), 1164-1176.
  32. Wormser, J., Lebret, M., & Le Neindre, A. (2017). L’échographie du diaphragme: principes et intérêts pour le kinésithérapeute. Kinésithérapie, la Revue, 17(182), 62-70.
  33. Gethin-Jones, T. L., Noble, V. E., & Morse, C. R. (2010). Quantification of diaphragm function using ultrasound: evaluation of a novel technique. Ultrasound in medicine & biology, 36(11), 1965-1969.
  34. Matamis, D., Soilemezi, E., Tsagourias, M., Akoumianaki, E., Dimassi, S., Boroli, F., ... & Brochard, L. (2013). Sonographic evaluation of the diaphragm in critically ill patients. Technique and clinical applications. Intensive care medicine, 39, 801-810.
  35. Kim, W. Y., Suh, H. J., Hong, S. B., Koh, Y., & Lim, C. M. (2011). Diaphragm dysfunction assessed by ultrasonography: influence on weaning from mechanical ventilation. Critical care medicine, 39(12), 2627-2630.
  36. Epelman, M., Navarro, O. M., Daneman, A., & Miller, S. F. (2005). M-mode sonography of diaphragmatic motion: description of technique and experience in 278 pediatric patients. Pediatric radiology, 35, 661-667.
  37. Richard, P. (2017). Exploration du diaphragme: l’échographie est incontournable. Revue des Maladies Respiratoires, 34(6), 645-660.

Become an Editorial Board Member

Become a Reviewer

What our clients say

MEDIRES PUBLISHING

At our organization, we prioritize excellence in supporting the endeavors of researchers and practitioners alike. With a commitment to inclusivity and diversity, our journals eagerly accept various article types, including but not limited to Research Papers, Review Articles, Short Communications, Case Reports, Mini-Reviews, Opinions, and Letters to the Editor.

This approach ensures a rich tapestry of scholarly contributions, fostering an environment ripe for intellectual exchange and advancement."

Contact Info

MEDIRES PUBLISHING LLC,
447 Broadway, 2nd Floor, Suite #1734,
New York, 10013, United States.
Phone: +1-(302)-231-2656
Email: info@mediresonline.org